Cargando…

A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 and piperaquine (PPQ)

Detalles Bibliográficos
Autores principales:	Stein, Daniel S, Jain, Jay Prakash, Lickliter, Jason, Kangas, Michael, Machineni, Surendra, Griffin, Paul, Lefevre, Gilbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179462/ http://dx.doi.org/10.1186/1475-2875-13-S1-P85

Ejemplares similares

Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
por: Lakshminarayana, Suresh B., et al.
Publicado: (2015)

A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
por: Leong, F. Joel, et al.
Publicado: (2014)

Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor
por: Goldgof, Gregory M., et al.
Publicado: (2016)

A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
por: Leong, Joel, et al.
Publicado: (2014)

Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand
por: Tarning, J, et al.
Publicado: (2014)

A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine
por: Leong, F. Joel, et al.
Publicado: (2018)

A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609
por: Zhang, Rou, et al.
Publicado: (2016)

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa
por: Ndayisaba, Gilles, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
por: White, Nicholas J.
Publicado: (2013)

Differences in the pharmacokinetics of currently approved antimalarial drugs in uncomplicated malaria patients compared to healthy subjects
por: Jain, Jay Prakash, et al.
Publicado: (2012)

Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria
por: Schmitt, Esther K, et al.
Publicado: (2021)

Pharmacokinetics‐Pharmacodynamics of High‐Dose Ivermectin with Dihydroartemisinin‐Piperaquine on Mosquitocidal Activity and QT‐Prolongation (IVERMAL)
por: Smit, Menno R., et al.
Publicado: (2018)

Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine
por: Permala, Jesmin, et al.
Publicado: (2017)

Development of the COVID-19 Perinatal Perception Questionnaire (COVID19-PPQ)
por: Hulsbosch, Lianne P., et al.
Publicado: (2021)

PDLIM5 links kidney anion exchanger 1 (kAE1) to ILK and is required for membrane targeting of kAE1
por: Su, Ya, et al.
Publicado: (2017)

Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
por: Wattanakul, Thanaporn, et al.
Publicado: (2021)

Fixed Dose Combination of Arterolane and Piperaquine: A Newer Prospect in Antimalarial Therapy
por: Patil, CY, et al.
Publicado: (2014)

Loss of kAE1 expression in collecting ducts of end-stage kidneys from a family with SLC4A1 G609R-associated distal renal tubular acidosis
por: Vichot, Alfred A., et al.
Publicado: (2017)

Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99–411, with long acting prescription antimalarials, lumefantrine and piperaquine
por: Taneja, Isha, et al.
Publicado: (2015)

Automated (90)Sr Separation and Preconcentration in a Lab-on-Valve System at Ppq Level
por: Vicente Vilas, Victor, et al.
Publicado: (2018)

Development of the 8-Item Phlegm Pattern Questionnaire (PPQ-8) Using Rasch Analysis
por: Park, Young-Jae
Publicado: (2021)

High Antimalarial Efficacy of Dihydroartemisinin–Piperaquine on the China–Myanmar Border: The Calm before the Storm
por: Fairhurst, Rick M.
Publicado: (2015)

Effect of mass dihydroartemisinin–piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance
por: Gupta, Himanshu, et al.
Publicado: (2020)

Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs
por: Wakoli, Dancan M., et al.
Publicado: (2022)

Improving Pharmacokinetic-Pharmacodynamic Modeling to Investigate Anti-Infective Chemotherapy with Application to the Current Generation of Antimalarial Drugs
por: Kay, Katherine, et al.
Publicado: (2013)

Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate
por: Wein, S, et al.
Publicado: (2012)

Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults
por: Banda, Clifford G., et al.
Publicado: (2018)

Nuclear Functions of KaeA, a Subunit of the KEOPS Complex in Aspergillus nidulans
por: Gawlik, Joanna, et al.
Publicado: (2022)

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers
por: Chotsiri, Palang, et al.
Publicado: (2017)

Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy
por: Chotsiri, Palang, et al.
Publicado: (2021)

Personally perceived publication pressure: revising the Publication Pressure Questionnaire (PPQ) by using work stress models
por: Haven, Tamarinde L., et al.
Publicado: (2019)

The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data
Publicado: (2013)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Efficacies of DHA–PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan
por: Mohamed, Abdelrahim O., et al.
Publicado: (2017)

Correction: The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data
Publicado: (2013)

Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine
por: Ross, Leila S., et al.
Publicado: (2018)

Pharmacokinetics of Piperaquine in Pregnant Women in Sudan with Uncomplicated Plasmodium falciparum Malaria
por: Adam, Ishag, et al.
Publicado: (2012)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
por: Minzi, Omary Mashiku, et al.
Publicado: (2021)

Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ(©))
por: Kaiser, Karen, et al.
Publicado: (2020)

KAE1 Allelic Variants Affect TORC1 Activation and Fermentation Kinetics in Saccharomyces cerevisiae
por: Kessi-Pérez, Eduardo I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9chr03kbbtbgh3i5rb1ngtqcu2